Linkedin Facebook Youtube

About Us

Arbele’s mission is to create more effective treatments for GI cancers

We are a clinical stage biotechnology company with our core proprietary technology platform centered on immunotherapy – TriAx Multispecific biologics as well as artificial-immunosurveillance AI-CAR technology for the treatment of gastrointestinal cancers. ​

​

Our main focus is on our proprietary biomarker, Cadherin-17 (CDH17), a highly specific target for GI cancers.
John Luk, DMedSc, EMBA
CEO & Founder
Read Bio
Dennis Wong, MD
Chief Medical Officer
Read Bio
Ms Khim Poon​
Chief Operating Officer
Read Bio
Dr Tony Wong, PhD
Chief Technology Officer
Read Bio
Jovey Chan, LLB, LLM(CFL)
Chief Legal Officer
Read Bio
Cindy Shek, BA
Co-founder & General Manager
Read Bio

Our Focus

Gastrointestinal Cancers

Gastrointestinal cancers presents a pressing challenge marked by unmet medical needs. Stomach, pancreas, colon, bile duct, and liver cancers collectively bear a significant burden, characterized by their high mortality rates and limited treatment alternatives. The complexity of these malignancies demands a new era of innovative therapeutic interventions that can effectively target the intricate molecular pathways driving tumor growth and progression. ​

​

Arbele is steadfast in its mission to bridge this therapeutic gap, pioneering groundbreaking drug development to provide hope and healing to patients grappling with these diseases. Our commitment to advancing scientific understanding and delivering novel solutions underscores our dedication to transforming the landscape of gastrointestinal cancer treatment.​

Image by kjpargeter on Freepik

Data from GLOBOCAN 2020; International Agency for Research on Cancer, WHO

Location: Seattle | Hong Kong | Guangzhou | Sydney | Singapore

Copyright©2023 Arbele All Rights Reserved.

error: Content is protected !!

John Luk, DMedSc, EMBA

Education and training at the University of Hong Kong, Karolinska (Stockholm) and Harvard (Boston)

Taught as academic professor for 18 years in the US, HK and Singapore

Published >200 papers including NEJM, Cell, Nature Medicine, Nature Genetics

Identified and patented CDH17 at HKU (Global License Arbele)

In 2011, moved to drug industry at senior leader position in Roche China and senior director in Johnson & Johnson Medical China to lead drug discovery and development programs in oncology, immunology and hepatitis

Former honorary professorship at leading institutions in HK, China and Asia; visiting associate professor at Harvard; established strong scientific, clinical and industrial networks globally

Dennis Wong, MD

Former VP Clinical Development of Sanofi in Asia Pacific

>20 years drug development in big pharma (Genentech, Roche, BMS and Sanofi)

Successful track records in FDA drug filing from FIH to NDA (with 5 BLA filed)

Board certified internal medicine, allergy & immunology

Harvard, UCSF, VCU, Chicago, Tokyo University

Ms Khim Poon​

Khim has worked in the Banking and Finance Industry for more thirty years in Singapore, Sydney Australia and Hong Kong.

She graduated with a Master of Applied Finance from University of Technology Sydney, Australia.

A SME in areas of credit risk & lending, general risk management, operations risk mapping, process controls and policies & procedures.

Dr Tony Wong, PhD

More than 10 years experience in drug development with multinational pharmaceutical companies and biotech startups

Target discovery, lead identification, optimization, Investigational New Drug (IND)-enabling studies and clinical trial designs

PhD (University of Hong Kong)

Jovey Chan, LLB, LLM(CFL)

HKU Law Graduate

15 years as a lawyer and legal counsel

Specialized practice in legal business, with rich M&A experience in technology & energy fields

Cindy Shek, BA

Specialized in public administration

20+ year experience in health care and hospital authority

Co-founding Tiberias Ltd, a HK biotech focusing on oncology drug development